EMA

AI-driven drug discovery — AlphaFold structure prediction, generative chemistry and physics-based virtual screening — compressing the target-to-candidate pipeline from years to months.

AI-assisted optical coherence tomography and fundus imaging for broad-disease eye screening — diabetic retinopathy, age-related macular degeneration and glaucoma — spanning home-use monitoring devices, multimodal clinic platforms and autonomous AI diagnostic software: Notal Vision and iHealthScreen in the US, Topcon Healthcare (Japan), RetinAI in Switzerland (acquired by EssilorLuxottica), and Airdoc in China.

AI interpretation of digitized whole-slide histology images using self-supervised vision transformers and attention multiple-instance learning to detect tumour foci, grade cancer (Gleason) and predict molecular biomarkers (MSI, PD-L1) from morphology, cutting diagnosis time from days to minutes.

Next-generation antimicrobial compounds and combinations designed to overcome multi-drug resistant (MDR) bacterial infections and address the global AMR crisis.

Targeted oncology therapies utilizing monoclonal antibodies to deliver highly potent cytotoxic payloads directly to cancer cells, minimizing systemic toxicity.

Integrated sterilising, filling and closing lines that deliver sterile injectables into vials, syringes and cartridges inside ISO 5 / Grade A isolator environments, engineered to meet the revised EU GMP Annex 1 and FDA sterility expectations.

Standalone machine-vision systems that inspect every filled vial, ampoule, syringe and cartridge for visible particulates, fill-level deviations, cosmetic glass defects and seal failures at line speed — a dedicated equipment category built around high-resolution cameras, multi-angle lighting and, increasingly, deep-learning defect classification under EU GMP Annex 1 and 21 CFR Part 11.

Utilizing naturally occurring or precision-engineered bacterial viruses to selectively target and eradicate specific pathogenic bacterial strains without harming the microbiome.

Base editors (CBE/ABE) make single-nucleotide changes C·G→T·A and A·T→G·C without double-strand breaks — treating monogenic disease (sickle cell, beta-thalassemia) at up to 90% efficiency with no indels.

The high-shear rotor-stator mixers, multi-shaft dispersers and monobloc cosmetic filling and packaging lines that turn oil and water phases plus recombinant actives into stable, cleanroom-grade emulsions — the manufacturing hardware behind clean-beauty, cell-culture-derived and biotech skincare.

Physical infrastructure for collecting, processing, cryopreserving and distributing human biospecimens at population or clinical-trial scale — the biospecimen logistics layer, not the genomic-data repository itself: UK Biobank in the EU, BioLife Solutions and Discovery Life Sciences in the US, the China National GeneBank in China, and the newly inaugurated Phenome-India National Biobank (CSIR-IGIB) in India.

Computation and storage carried out in molecules and living tissue rather than silicon — DNA archives with in-sequencer random access, error-correction codecs tolerating error rates near 14% and sequence loss up to 65%, genetic circuits implementing half and full adders, and biohybrid systems that compute with slime mould and fungal networks.

Bio-based dyes and pigments produced via microbial fermentation and synthetic biology.

Electroceutical devices that treat disease by electrically stimulating nerves rather than with drugs — vagus and splenic nerve neuroimmune modulation, AI-personalized spinal cord stimulation, hypoglossal nerve stimulation and implantable neuromodulation for paralysis and neurological disease: SetPoint Medical, Nevro Corp and Inspire Medical Systems in the US, Galvani Bioelectronics and Onward Medical in Europe, and PINS Medical in China.

Sequencing, single-cell and spatial omics, and biological AI that turn raw reads into decisions — a stack from sample to interpreted multi-omics.

The AI, machine-learning and bioinformatics software-as-a-service layer — cloud platforms, generative biological foundation models and managed analysis pipelines — sold to pharma, biotech and industrial-biology teams rather than run as in-house drug pipelines.

Biologics — monoclonal antibodies, ADCs, CAR-T and gene therapy — are the largest and fastest-growing drug class, built on a reproducible cell-line platform at 2–10 g/L titers.

Engineered luciferases and fluorescent proteins derived from jellyfish, deep-sea shrimp and other marine organisms, redesigned via directed evolution and computational protein design into ultra-bright, photostable research tools for drug screening, cell imaging and protein-protein interaction detection.

The engineering of medical devices that interface with the body — orthopedic, cardiovascular and neuro implants — sold as capital robotic systems, per-procedure implants and regulated biomaterials under FDA, EU MDR and NMPA oversight.

Bio-inspired surgical adhesives, sealants and hemostatic gels that bond, seal or stop bleeding in wet tissue environments where conventional sutures and staples struggle — drawing on biological adhesion mechanisms such as mussel/oyster adhesive proteins: Tissium in France, Cresilon and Brij Medical in the US, and Adhesys Medical in Germany.

Prosthetic devices that replace a lost limb's function through AI-driven control, touch sensing and direct skeletal attachment — dexterous touch-sensing hands, AI neural prosthetic control, myoelectric pattern recognition and osseointegrated prostheses: Psyonic, Atom Limbs and Coapt in the US, Ottobock and Integrum in Europe, and BrainCo (BrainRobotics) in China.

Large-molecule therapeutics manufactured via living cells to treat complex diseases like cancer, diabetes, and autoimmune disorders.

In-line sensing, chromatography and mass spectrometry that turn biomanufacturing into data-driven, feedback-controlled production — a stack from probe to real-time release.

Contract development and manufacturing organizations providing specialized infrastructure for advanced biopharmaceuticals.

Physical-containment infrastructure — biological safety cabinets, HEPA filtration, autoclave sterilization and BSL-1 to BSL-4 containment — that protects personnel, product and environment in every biotechnology laboratory, governed by NSF/ANSI 49 and EN 12469.

Advanced inline and online bioprocess sensors utilizing optics, capacitance, and spectrometry for real-time monitoring of biomass, metabolites, and dissolved gases in industrial fermentation.

Temperature-controlled, chain-of-custody transport and storage of patient-derived samples between trial sites, central labs, and biorepositories.

Producing CBD, THC and rare cannabinoids (CBG, CBDV, THCV) as platform molecules via engineered yeast fermentation and chemo-enzymatic synthesis, bypassing plant cultivation.

Microbial precision fermentation of hyaluronic acid to a defined molecular weight and pharmacopoeia-grade purity — a B2B biopolymer API for ophthalmic viscoelastics, dermal fillers, orthopedic viscosupplementation and premium cosmetics, under FDA, EMA and NMPA oversight.

Corticosteroid and reproductive-hormone APIs made by mycobacterial fermentation of phytosterol into AD/ADD/9-OHAD precursors, then biocatalytic and semi-synthetic finishing — a globally-offshored manufacturing tier anchored by Olon, Farmabios and Gadea in Europe, Tianjin Tianyao in China, Symbiotec in India and Asymchem's biocatalysis CDMO.

Specialty insurance and brokerage services covering bodily injury and property damage claims arising from biotechnology and pharmaceutical products, structured as layered towers and paired with clinical-trial, E&O and recall coverage.

Engineered antibodies that bind two (or more) antigens on one molecule — most powerfully a CD3 arm that recruits the patient's own T cells to a tumour cell — delivered off-the-shelf as approved drugs across lymphoma and myeloma by Roche, Janssen, Regeneron, AbbVie/Genmab and BeiGene.

Non-invasive breath analysis using VOC patterns for early diagnosis and continuous disease monitoring.

A patient's own T cells are collected, engineered with a chimeric antigen receptor (CAR) using a lentiviral vector, expanded and re-infused to kill cancer — an approved one-time living-drug class spanning CD19 lymphoma/leukemia and BCMA multiple myeloma, now advancing toward off-the-shelf allogeneic products.

Cell-free protein synthesis (CFPS) bypasses the living cell: ribosomes and translation factors in a reaction tube deliver the target protein in hours, not weeks, with toxic and non-canonical amino acids incorporated.

Engineered-enzyme steps (transaminases, ketoreductases, lipases) substituted into small-molecule API routes to replace metal-catalysed or multi-step chemical sequences — anchored by Codexis's CodeEvolver platform (the Merck sitagliptin transaminase case) in the US, Almac's biocatalysis CDMO in the UK, Lonza's HPAPI/biocatalysis toolkit in Switzerland, and Asymchem and WuXi AppTec's biocatalysis-enabled CDMO platforms in China.

Multi-tenant, remotely operated wet labs that execute user-submitted protocols via API and return structured data — the layer that turns biology into programmable infrastructure, decoupling experiment design from bench work and feeding the closed-loop AI-driven autonomous lab.

Specialized strategic advisory services guiding biopharma through the complex Chemistry, Manufacturing, and Controls (CMC) requirements to successfully file Biologics License Applications (BLA) and Marketing Authorisation Applications (MAA).

Robotic platforms that image a microbial plate, score colonies by size, morphology and fluorescence, then pick and re-array 200–3,000 colonies an hour into fresh growth plates — the automated front end of strain engineering, directed evolution, CRISPR clone screening and microbiome culturomics.

Tissue-based immunohistochemistry (IHC) and FISH platforms that determine whether a specific patient is eligible for a specific targeted therapy, sold and regulated as a companion diagnostic (CDx) tied directly to a drug label — distinct from blood-based liquid-biopsy CDx: Ventana/Roche Tissue Diagnostics, Agilent Dako and Myriad Genetics in the US, 3D Medicines in China, and MedGenome in India.

Dry-electrode EEG wearables — headbands, earbuds and sleep masks — that read brainwave activity without gel or clinical setup, using on-device AI artifact removal and neurofeedback training to support meditation, focus and sleep, regulated as general wellness devices rather than medical BCI.

Pharma-sponsored accelerators and shared wet-lab hubs — JLABS, Bayer Co.Lab/G4A, Boehringer Ingelheim's BI X programs — that give startups equity-free or seed-funded access to lab infrastructure and IND-track mentorship in exchange for first-look licensing or M&A rights.

Outsourced, regulator-aligned training services that build and maintain GMP, GLP and GCP competency across biopharma workforces, producing inspection-ready training records under 21 CFR Part 11, EU GMP and ICH guidelines.

Cas-enzyme nucleic-acid detection — point-of-care molecular diagnostics from sample to lateral-flow readout.

Contract functional-genetic CRISPR screening (pooled sgRNA libraries, lentiviral delivery, NGS) — identifies cancer-resistance genes and drug targets in weeks.

Regulation Crowdfunding platforms and decentralized-science (DeSci) DAOs that let non-accredited retail investors fund early-stage biotech directly — via equity stakes or tokenized IP-NFTs — for projects too early-stage for traditional venture capital.

The stirred, draft-tube-baffled, melt and continuous crystallizers — plus the inline FBRM/PVM probes that close the loop on them — that turn a purified API molecule into a defined polymorph with a target particle-size distribution, the unit operation on which bioavailability, purity and downstream filterability all depend.

Advanced analytical devices detecting biological markers to enable rapid, precise disease identification and monitoring.

Software-as-medical-device treatments that deliver a regulator-cleared clinical intervention rather than general wellness support — prescription digital therapeutics for ADHD, insomnia, anxiety and depression, musculoskeletal digital rehabilitation and pediatric autism intervention: Akili Interactive, Big Health and Click Therapeutics in the US, Kaia Health in Germany, and ALSOLIFE in China.

High-speed centrifugal separators that stack conical discs to multiply settling area, clarifying fermentation broth and cell culture at 5,000–15,000 ×g with continuous automatic solids discharge — the primary harvest and clarification machine of bioprocessing, now extending into gamma-irradiated single-use bowls for small-batch and perfusion work.

Folding single-stranded DNA into precision-programmed 3D nanostructures — drug-delivery nanorobots, vaccine scaffolds and metrology nanorulers.

The commercial gene-synthesis service and biofoundry layer of synthetic biology — turning digital DNA designs into delivered genes, clones and strain builds through phosphoramidite and emerging enzymatic synthesis, governed by pathogen-sequence biosecurity screening.

Downstream purification converts crude bioreactor harvests into clinical-grade drug substance — chromatography (Protein A, IEX, HIC), tangential-flow filtration, and viral clearance together account for >50% of biomanufacturing CAPEX. The global DSP market exceeds $5B and grows at >8% CAGR driven by mAb and cell-gene therapy demand.

The end-to-end R&D pipeline that carries a drug or vaccine candidate from target identification through Phase I-IV clinical trials to regulatory approval — a 7-15-year, billion-dollar process now being reshaped by personalized mRNA platforms, GLP-1 blockbuster economics and competing FDA, EMA and NMPA regulatory-acceleration reforms.

Direct-to-consumer genetic testing from saliva via SNP genotyping arrays and 30x whole-genome sequencing, with bioinformatic polygenic risk scoring and telemedicine gating of pathogenic findings (BRCA1/2), under FDA 510(k), EU IVDR and China's genetic-data sovereignty rules.

Deliberately engineering whole wild populations — from CRISPR gene drives that force 100% inheritance of a trait through a mosquito population in 6-20 generations to Wolbachia-infected and radiation-sterilized releases that collapse it instead — as a genetic complement to nature-based ecological engineering like constructed wetlands and living shorelines, all governed by an irreversibility problem no field release can undo.

Cell-free directed synthesis of high-molecular-weight polymers utilizing purified recombinant enzymes ex vivo, eliminating metabolic constraints to produce ultra-pure biomaterials for regenerative medicine and high-end cosmetics.

Engineered enzymes and enzyme-target inhibitors are moving toward pharmaceutical protection from gluten exposure in celiac disease — a Barcelona-designed gastric enzyme validated in mouse models, a transglutaminase-2 inhibitor showing histologic protection in human trials, and a $35M Takeda-funded oral enzyme program whose later trial stage reportedly worsened mucosal damage.

Reading DNA-methylation patterns across hundreds of thousands of CpG sites to compute a person's biological age and pace of aging, rather than the calendar age on a birth certificate, turning a $229-799 saliva or blood test into the primary read-out for the longevity industry.

Turning genes on or off by rewriting DNA methylation and histone marks with dCas9 fusion proteins or zinc fingers — no DNA sequence change, but an effect that can be inherited across cell divisions.

Non-invasive breath-analyte devices aiming to monitor diabetes-relevant metabolic state without a fingerstick or implanted sensor — most commercially advanced platforms detect breath acetone/ketones as a metabolic proxy, while newer entrants target a more direct blood-glucose alert claim: PranaQ, Invoy Technologies, LEVL and PREEVNT, all US-based.

Cell-derived nanoscale vesicles (30-150 nm) used as native regenerative-medicine agents or engineered as biocompatible drug-delivery vehicles for RNA, protein and gene-editing cargo, crossing biological barriers artificial lipid nanoparticles cannot.

Specialized biologic, diagnostic and live-biotherapeutic products for conditions that affect exclusively or disproportionately women — non-invasive endometriosis testing, ovarian-longevity therapeutics, vaginal-microbiome LBPs and cfDNA prenatal screening, under FDA, EU IVDR/EMA and NMPA oversight.

Matching platforms and contract manufacturers that connect biotech companies needing fermentation capacity with idle or available bioreactor capacity, easing the scale-up bottleneck between lab-scale precision fermentation and commercial-volume production.

High-precision sterile filling of advanced biological drugs into final delivery formats using isolated robotic environments.

Precision delivery of functional genetic material via engineered vectors to treat inherited diseases and severe genetic disorders at their root cause.

Creating completely novel, non-natural protein structures and sequences from scratch using diffusion networks and large language models for therapeutics and biosensors.

Programmable genome editors — CRISPR-Cas9, base editors and prime editors — delivered ex vivo or in vivo via lipid nanoparticles to treat genetic disease, from the first approved CRISPR therapy Casgevy to in-vivo redosable CRISPR and single-dose cardiovascular base editing.

Sequencing-based services that track pathogen genomic evolution and spread for public health response — traveler/airport biosurveillance, portable field sequencing and national metagenomic surveillance programs — the genomic-analysis service layer, not the sample-collection infrastructure: Ginkgo Bioworks (Concentric) in the US, Oxford Nanopore Technologies and the Wellcome Sanger Institute/UKHSA in the UK, BGI Genomics in China, and the Rajiv Gandhi Centre for Biotechnology in India.

Writing genomes rather than just reading them — DNA synthesis at scale, de novo synthetic chromosomes and DNA-based digital data storage, complementing the sequencing/analysis side of genomics.

Selectively clearing senescent 'zombie' cells or suppressing their inflammatory secretome to treat age-related disease at its molecular root, rather than one downstream condition at a time.

Regulated door-to-door transport of Category A and B infectious substances under IATA Packing Instructions 602/650, using triple packaging, biosafety couriers and chain-of-custody tracking.

Self-administered blood collection for consumer health testing, either mailed to a certified laboratory or drawn at a retail microsample station, returning results outside a clinic visit — distinct from clinic point-of-care testing: LetsGetChecked and Everlywell (mail-in kits) and Babson Diagnostics (retail microsample testing) in the US, and Thriva in the UK.

Surgically or subcutaneously implanted sensors that continuously monitor a chronic-disease parameter for months to years without an external wearable — implantable continuous glucose monitors and insertable cardiac monitors — distinct from external wearables and ingested/swallowed sensors: Senseonics' Eversense 365 in the US, Medtronic's LINQ II and Boston Scientific's LUX-Dx cardiac monitors in the US, Biotronik's BIOMONITOR in Germany, and MicroPort in China.

Deriving functional human eggs and sperm entirely outside the body from reprogrammed stem cells, aimed at reversing absolute infertility and enabling genome-corrected embryos.

One-time, potentially curative genetic medicines delivered by engineered adeno-associated and lentiviral vectors — eight FDA-approved in-vivo products since 2017, from Luxturna to Beqvez, now a multi-billion-dollar clinical reality alongside honest commercial retrenchments.

Swallowed capsule devices that image the GI tract or confirm medication ingestion as they transit the body, requiring no sedation or implantation — distinct from surgically implanted sensors: Medtronic's PillCam and CapsoVision's CapsoCam capsule endoscopy in the US, etectRx's ID-Cap ingestible event marker in the US, and Ankon Technologies' magnetically controlled capsule endoscopy in China.

Real-time, in-the-operating-room molecular and optical tissue identification — fluorescence imaging agents, OCT, stimulated Raman histology and mass-spectrometry tissue analysis — that lets surgeons assess tumor margins during the procedure instead of waiting on frozen-section pathology: On Target Laboratories and Dilon Technologies (fluorescence/RF-spectroscopy margin agents), Perimeter Medical Imaging AI (AI-enabled OCT), Invenio Imaging (stimulated Raman histology) in the US, and photonamic and Imperial College London (iKnife/REIMS) in Europe.

High-throughput robotic liquid handling systems and integrated laboratory automation platforms that exponentially increase assay throughput, eliminate human error, and enable next-generation genomics and synthetic biology.

High-throughput robotic systems and liquid handling workstations driving autonomous, reproducible bio-research and screening.

Integrated Laboratory Information Management Systems (LIMS) and Electronic Lab Notebooks (ELN) serving as the digital backbone for biopharma R&D, cell line development, and cGMP commercial manufacturing.

Blood-based detection and quantification of circulating tumor DNA (ctDNA) for cancer companion diagnostics and molecular residual disease (MRD) monitoring, replacing or supplementing tissue biopsy — led by Guardant Health, Natera and Foundation Medicine in the US, Sysmex Inostics in the EU, MedGenome in India, and Burning Rock Biotech in China.

Viability-preserving cold-chain last-mile delivery of live microbial biopreparations — phages, probiotics and biofertilizers — using PCM isothermal packaging, IoT loggers and PMA-qPCR viability audit at the point of application.

Contract development, technology-transfer and local-build services that establish in-country or regional biomanufacturing so a biologic or vaccine qualifies for market access, procurement preference and supply security in target jurisdictions.

Vacuum freeze-drying systems that sublime ice from filled vials to yield shelf-stable lyophilized biologics, vaccines and injectables, engineered around controlled ice nucleation, natural refrigerants and PAT/RTRT cycle control under EU GMP Annex 1 and ICH Q13.

GMP equipment lines for B2B dry-powder and liquid cell-culture media — cryogenic pin milling, ribbon-blend homogenisation and 0.1 um sterile fill — supplying the chemically-defined, animal-component-free media demand of mAb and cell-therapy biomanufacturing.

Surface-engineering and coating technologies that govern how a catheter, guidewire, stent or implant actually meets living tissue — hydrophilic lubricious coatings, bioactive anticoagulant polymer layers, and drug-eluting coating systems — spanning Formacoat, Biocoat and Integer Holdings in the US, Freudenberg Medical and DSM Biomedical in Europe, and Sino Medical Sciences Technology in China.

Contract research platforms that profile the small-molecule metabolome of blood, tissue or bioreactor broth via LC-MS/GC-MS, turning raw chromatography data into biomarker panels, drug-response readouts and bioprocess metabolic profiles for pharma, nutrition and industrial-fermentation clients.

Stool- or swab-based sequencing panels that profile the gut or GI microbiome for consumer wellness insight or clinical pathogen/dysbiosis detection, distinct from general human genomics services: Viome (US, consumer wellness) and Codex Genetics (US, clinical metagenomics), Sequentia Biotech's IVDR-CE-marked MICK Clinical in Spain, Realbio Genomics in China, and Yaazh Xenomics in India.

Live biotherapeutic products (LBPs) — standardized, GMP-manufactured microbial consortia approved as drugs for recurrent C. difficile, inflammatory bowel disease and immuno-oncology support.

Small (100–300 μm) suspended particles whose surface lets anchorage-dependent cells grow inside ordinary stirred-tank and single-use bioreactors — the consumable that turns adherent biology (vaccines, cell therapy, cultivated meat) into a scalable, GMP industrial process.

Automated mini- and micro-bioreactors (1-250 mL) running 24-48 cultures in parallel that map a bioprocess Design Space in days rather than months — the high-throughput on-ramp to cell-line, strain and upstream-process development, led by the German ambr, BioLector and DASbox platforms.

Prefabricated, autonomous cleanroom infrastructures delivering rapid deployment, scalable capacity, and guaranteed cGMP compliance for the rapidly evolving biomanufacturing and cell therapy sectors.

The mixers, skids and continuous-flow reactors that bring an mRNA payload and a four-lipid ethanol blend together in microseconds to self-assemble 80–120 nm lipid nanoparticles — the hardware layer behind every commercial mRNA vaccine and the in-vivo delivery system for the next generation of gene therapy.

Synthetic mRNA in lipid nanoparticles (60–100 nm) turns the cell into a bioreactor — from a vaccine platform to personalised cancer immunotherapy and in-vivo protein expression.

A single blood draw screening asymptomatic, average-risk individuals for signals of dozens of cancer types simultaneously, aiming to catch cancer before symptoms appear — distinct from treatment-matched companion diagnostics: GRAIL's Galleri (US), Exact Sciences' Cancerguard (US) and Freenome (US), Novigenix in Switzerland, and Singlera Genomics in China.

Integrative genomic, transcriptomic and proteomic oncology profiling platforms that combine multiple molecular data layers into a single treatment-matching report, broader than a single drug-label companion diagnostic: Tempus AI and Caris Life Sciences in the US, Sophia Genetics in Switzerland, Geneseeq Technology in China, and 1cell.ai in India.

Regulated pre-approval access to investigational biopharmaceuticals for patients with serious or life-threatening disease and no satisfactory alternative — operated as a managed-access service spanning eligibility, regulatory submission, GMP drug sourcing and pharmacovigilance.

Brain–computer interfaces that read motor and speech cortex activity and decode intent into text, synthesized voice or robotic movement — spanning invasive intracortical arrays, endovascular stent-electrodes, semi-invasive ECoG and non-invasive EEG, under FDA IDE trials, EU MDR and NMPA oversight.

CAR-NK and NK-cell therapy — allogeneic, off-the-shelf effector cells with low toxicity (minimal CRS, no GVHD) against solid and haematological cancers; iPSC-NK is the scalable platform.

Short synthetic oligonucleotides — siRNA and antisense — bind a target messenger RNA to silence or reprogram a disease gene, enabled by GalNAc liver targeting and sugar/backbone chemistries, with multiple approved drugs across rare, neurological and cardiometabolic disease.

Additive manufacturing of living cells and biomaterials to construct functional tissue models and transplantable organs.

Microphysiological systems mimicking human organs in vitro to replace animal testing and accelerate personalized medicine.

Transient expression of Yamanaka reprogramming factors to reverse epigenetic markers of cellular aging without erasing cell identity — OSK gene therapy, AI-discovered reprogramming payloads and safer single-gene rejuvenation targets: Altos Labs, Retro Biosciences, NewLimit and Life Biosciences in the US, Shift Bioscience in the UK, and JingTong Life in China.

Computational patient models and virtual trial simulations used to reduce, accelerate or de-risk clinical development — AI-generated synthetic control arms, physiologically-based pharmacokinetic modeling, preclinical-to-clinical translation AI and causal-AI virtual patient simulation: Unlearn.AI, Certara and VeriSIM Life in the US, and Novadiscovery (Nova In Silico) in France.

Gene and cell therapy platforms for rare monogenic and oncological diseases: AAV vectors, lentiviral HSC editing, ex vivo CRISPR (Casgevy) and in vivo CRISPR (LNP delivery) now deliver durable one-time treatments approved by FDA and EMA.

Molecular diagnostics leveraging NGS, liquid biopsy, and AI for precision medicine and targeted therapies.

Advanced bioremediation targeting per- and polyfluoroalkyl substances (PFAS) using engineered proteins, specialized microbial consortia, and bio-based adsorbents to break down forever chemicals.

Lab-free, sample-to-answer molecular testing platforms delivering PCR-grade results at the bedside, clinic or field site in minutes rather than the hours a central lab requires: Cepheid's GeneXpert (Danaher) and bioMérieux's BIOFIRE cartridge-based systems, Abbott's ID NOW isothermal platform, Sansure Biotech's domestic POCT scale-up in China, and Molbio Diagnostics' Truenat chip-based platform serving resource-limited settings from India.

Search-and-replace genome editing with a Cas9 nickase fused to a reverse transcriptase and an extended pegRNA — writing all 12 base substitutions and small indels without a double-strand break.

CRO-delivered three-stage process validation and IQ/OQ/PQ qualification of biopharma equipment — media fills, cleaning validation, CSV and viral clearance under FDA/EudraLex Annex 1 cGMP.

Bifunctional small molecules that recruit an E3 ubiquitin ligase to a disease protein, tagging it for proteasomal destruction — an event-driven, catalytic drug modality approaching its first approval with Arvinas's estrogen-receptor degrader vepdegestrant, and a deep pipeline across IRAK4, IKZF and BTK targets.

Mass-spectrometry proteomics as a contract research service — deep DIA proteome profiling, targeted MRM/PRM and affinity proteomics for biomarker discovery and pharmacoproteomics.

Psychoactive-compound therapies (psilocybin, MDMA, 5-MeO-DMT) and next-generation non-hallucinogenic psychoplastogens that trigger rapid synaptogenesis via serotonin 5-HT2A receptor signaling, targeting treatment-resistant depression and PTSD — a field with genuine 2026 clinical wins and a high-profile FDA regulatory setback.

Radioactive compounds that pair a tumor-targeting vector with a diagnostic or therapeutic isotope — 'see what you treat, treat what you see' — now commercial at multi-hundred-million-dollar manufacturing scale.

Platforms that determine which antibiotics a specific infecting pathogen is susceptible or resistant to in hours instead of the 2-3 days conventional culture-based susceptibility testing requires, guiding targeted rather than empiric antibiotic therapy: Accelerate Diagnostics and T2 Biosystems and Selux Diagnostics in the US, Q-linea in Sweden, and Autobio Diagnostics in China.

Recombinant and next-generation engineered botulinum neurotoxins (BoNT) — expressed via DNA technology or reformulated as complex-free / ready-to-use liquids — are displacing traditional Clostridium botulinum fermentation: AbbVie/Allergan's Boey® (trenibotulinumtoxinE, recombinant serotype E) won EU and Health Canada approval in 2026 with onset as early as 8 hours and a 2-3 week duration across 2,100+ Phase 3 patients; Galderma's Relfydess™ (relabotulinumtoxinA, PEARL™ Technology ready-to-use liquid) reached 33 markets including EU approval across 16 countries in 2026; Merz's Xeomin (incobotulinumtoxinA, complexing-protein-free naked toxin) holds 79-country approval; Eirion's AI-09 ready-to-use recombinant liquid injectable achieved 6-month duration at the highest dose in a 96-subject Phase 1-2 trial. China's Lanzhou/CNBG Hengli® (衡力) — the country's first domestic BoNT-A (2002 approval, 30+ years lineage) — leads the local market with first-in-China 2025-2026 approvals for axillary hyperhidrosis and benign masseter hypertrophy while domestic recombinant R&D remains pre-commercial.

Precision-fermentation-derived collagen and gelatin — produced in engineered yeast or via plant molecular farming rather than animal hide and bone extraction — for food, dietary-supplement, wound-care and tissue-engineering applications, eliminating prion-contamination risk and batch variability.

Precision-fermentation collagen engineered specifically for skincare and injectable aesthetic medicine — matching the human collagen sequence, free of prion and allergenicity risk, and small enough to penetrate skin's epidermal barrier — powering China's dominant recombinant-collagen skincare industry and premium Western dermal-filler and cosmetic-ingredient lines.

Recombinant human serum albumin (rHSA) replaces plasma-derived HSA (pHSA) — constrained by donor blood supply and viral contamination risk since the 1940s — with biosynthetic production in yeast (Pichia pastoris, Hansenula polymorpha) or plant (rice endosperm) hosts: Healthgen Biotech's OsrHSA (奥福民®) became the world's first NMPA-approved rHSA injection (July 2025) with 1-million-vial annual capacity and a 22-centre Phase III in decompensated liver cirrhosis; InVitria's Exbumin (rice-derived, ExpressTec platform) is the excipient in Merck's ERVEBO Ebola vaccine — the first FDA/EMA/PMDA-approved rice rHSA in an injectable — and Optibumin 25 (launched April 2025) is the first recombinant 25% HSA for closed-system biomanufacturing; Proliant launched AlbufreeDX (June 24, 2026) for diagnostics; Basic Pharma (NL) + ARTES Biotechnology (DE) make Hansenula polymorpha rHSA; Shilpa Medicare's sRbumin® became India's first rHA Phase 1 completion (August 2024), with CDSCO Phase III nod (November 2024) and an Orion Europe commercialization deal. The global rHSA market stood at USD 166M in 2025, projected to USD 421M by 2035 (CAGR 9.75%).

Authenticated microbial type strains and WHO biological reference materials — the calibrated living standards underpinning pharmaceutical QC, diagnostics, taxonomy and patent deposit, held by a global network of biological resource centers from the century-old ATCC to NIBSC.

Eye-scan technologies that detect Alzheimer's and other neurodegenerative-disease biomarkers directly in the retina — a window onto brain pathology accessible without imaging the brain itself — spanning hyperspectral imaging, OCT-based structural biomarkers and retinal amyloid detection: RetiSpec and NeuroVision Imaging in North America, Optina Diagnostics in Canada, and Heidelberg Engineering in Germany.

Engineered oligonucleotides that recruit the cell's endogenous ADAR enzymes to rewrite a pathogenic adenosine to inosine on disease transcripts — a reversible, titratable alternative to DNA editing now in clinical validation, with Wave's WVE-006 (AATD, RestorAATion-2) the lead asset and ProQR's Axiomer platform delivering the first clinical proof of mechanism.

Industrial automation software orchestrating complex bioreactor operations and enforcing regulatory compliance through electronic batch records.

The vision inspection, 2D-Data-Matrix printing, aggregation and multi-enterprise network software that stamp a unique identity onto every saleable drug unit and follow it from factory to dispenser — the equipment layer that makes pharma supply chains DSCSA-, FMD- and China-code-compliant, anti-counterfeit and recall-ready.

Recombinant silk fibroin and spider-silk proteins — expressed via microbial precision fermentation (Spiber Brewed Protein™, AMSilk Biosteel, Bolt Threads MicroSilk), transgenic *Bombyx mori* silkworms (Kraig Biocraft MaSp1/MaSp2), or purified from *Bombyx mori* cocoons for biomaterials (Sofregen Medical SilkVoice FDA-cleared ENT device) — have crossed into commercial scale in 2026: Spiber's Rayong Thailand plant and 2025 Italian-mill partnerships (Botto Giuseppe, Manifattura Sesia, Achille Pinto) produced 100% Brewed Protein yarns at industrial tonnage; AMSilk's bioengineered yarns debuted in Balenciaga Spring 2026 collection and Ajinomoto Foods Europe's dedicated 160 m³ Nesle France fermentation plant came online July 2026; Kraig Biocraft hit 1.3 metric tons of recombinant spider silk cocoons in March 2026 (1.8 MT in April) via transgenic silkworms in Vietnam; Sofregen Medical's SilkVoice holds two FDA 510(k) clearances (K180631, K240919) for vocal cord medialization, validated in a 33-patient Laryngoscope 2026 study. Bolt Threads patented recombinant silk polypeptide as a silicone replacement in personal care (US20260069524A1, March 2026).

Per-cell mapping of genomes, transcriptomes and proteomes as a contracted service — moving biology from bulk-average reads to cell-by-cell atlases for drug-target discovery and patient stratification.

Pre-sterilized, fully integrated polymer fluid paths and containment bags that eliminate cross-contamination, bypass intensive cleaning validation, and drastically compress biomanufacturing facility footprints.

Gamma-irradiated single-use bag bioreactors in the 50-2000 L stirred-tank class — Sartorius Biostat STR, Cytiva Xcellerex XDR, Thermo Fisher HyPerforma, Merck Mobius — that replaced stainless steel for clinical and commercial mAb, vaccine and cell-and-gene-therapy manufacturing, cutting facility build-out from years to weeks and underpinning the CDMO economy.

Disposable bioreactors, bags and tubing plus modular factories (KUBio — 12–18 months vs 5–7 years) cut capex and cross-contamination, making biomanufacturing flexible and multi-product.

Mapping chromatin accessibility, DNA methylation and histone marks directly on a tissue section instead of a dissociated cell suspension, using in situ Tn5 transposition and microfluidic barcoding to build 3D atlases of a tumor's epigenetic state at 10-micron resolution — the layer of hardware and reagents beneath precision oncology's biggest 2026 push.

Mapping gene expression — and increasingly proteins — directly onto intact tissue sections, so each transcript keeps its x/y address and the tumour microenvironment becomes a navigable map rather than a bulk average.

Living mesenchymal stromal cells (MSC) or regulatory T cells (Treg) are infused to re-tolerise the immune system in autoimmune and inflammatory disease — an approved-asset class led by Mesoblast's Ryoncil for steroid-refractory GVHD and TiGenix's Alofisel for Crohn's fistula, with a deeper engineered-Treg pipeline for lupus, arthritis and aplastic anemia.

Cryo-electron microscopy as a contract research service — atomic 3D structures of membrane proteins and drug targets for structure-based drug design, displacing X-ray crystallography.

The engineering of biology — designing DNA, cells and genetic circuits on computers, building them in biofoundries and scaling them into chemicals, materials and ingredients through the Design-Build-Test-Learn cycle.

Engineered, exogenous reporter molecules — activity-based nanosensors, synthetic gene circuits and volatile-organic-compound probes — administered to a patient to generate an amplified, easily measured disease signal that no endogenous biomarker naturally produces: Glympse Bio, Earli and ZymoSense in the US, and Owlstone Medical's EVOC breath-probe platform in the UK.

Patient T cells are engineered with a high-affinity T-cell receptor (TCR) that recognises a peptide-MHC complex inside a solid-tumour cell — an approved one-time therapy reaching tumour targets CAR-T cannot, led by Adaptimmune's Tecelra and Immunocore's Kimmtrak, with a deeper pipeline advancing MAGE-A4, NY-ESO-1, gp100 and PRAME targets.

Point-of-care diagnostic testing of a microliter tear sample for dry eye, ocular allergy and inflammatory biomarkers, avoiding blood draw or invasive sampling: Trukera Medical's tear osmolarity system and Lacrisciences' tear IgE allergy test and QuidelOrtho's InflammaDry inflammatory marker test in the US, and DiagnosTear's TearX platform in France.

Advanced process simulation and financial modeling services that determine the commercial viability, optimal facility sizing, and Cost of Goods Sold (COGS) for emerging biomanufacturing technologies before capital is deployed.

TIL therapy — autologous tumor-infiltrating T-cells with polyclonal specificity; the first approved drug Lifileucel (Amtagvi, Iovance, FDA 2024) is a breakthrough in metastatic melanoma.

Contract safety assessment that takes a drug candidate from in-silico ADMET triage through in-vitro panels (hepatotoxicity, hERG, CYP induction) to GLP in-vivo studies, delivering the IND-enabling toxicity package regulators require — now augmented by toxicogenomics and virtual control groups.

Specialized venture studios, wet-lab accelerators and academic nonprofit networks that convert university biotech IP into funded companies, closing the gap between a PhD discovery and a commercial spin-off.

Advanced veterinary biotechnology focusing on mRNA vaccines, recombinant proteins, and novel biologics to combat zoonotic and livestock diseases with rapid-response platforms.

Direct-to-consumer DNA testing of dogs and cats — a stack from cheek-swab collection to a LIMS-verified veterinary genetic passport screening hundreds of inherited disease risks.

Aggregate, non-invasive molecular surveillance of municipal sewage for pathogens, antimicrobial resistance and substance use — an early-warning public-health intelligence service built on viral concentration, droplet-digital PCR and metagenomic sequencing.

Wearable biodiagnostics and continuous monitoring systems enabling real-time precision health management.

Transplanting organs from multiplex gene-edited pigs into humans to address the chronic shortage of donor organs, now moving from expanded-access compassionate cases into FDA-cleared clinical trials.